Denise Braendgaard: We are Now the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
Denise Braendgaard, General Manager of Novo Nordisk Haemophilia Foundation, shared a post by Novo Nordisk Haemophilia & Haemoglobinopathies Foundation on LinkedIn:
”The day has finally arrived and I can’t hide my excitement: we are waking up to new horizons.
After years of preparation by our Council and Team – and inspired by our incredible partners – we are immensely proud to announce that we are now the Novo Nordisk Haemophilia & Haemoglobinopathies Foundation.
It is much more than adding one word.
It represents hope for people affected by haemoglobinopathies – specifically sickle cell disease and thalassaemia – in low and middle income countries who will benefit from our programmes. At the same time, it reaffirms our unwavering commitment to haemophilia.
It is an expansion of our vision and scope, a bold declaration of our continued, long-term dedication after 20 years of Impacting Care. Together.”
Quoting Novo Nordisk Haemophilia & Haemoglobinopathies Foundation’s post:
”We are now the Novo Nordisk Haemophilia & Haemoglobinopathies Foundation
Proudly, we are unveiling our Foundation’s new chapter:
We are expanding our support beyond people with haemophilia to people with sickle cell disease and thalassaemia as well.
Building on two decades of work in haemophilia, and enabled by a renewed partnership with the Novo Nordisk Foundation and the continued funding from our founder, Novo Nordisk, we are expanding our scope to include haemoglobinopathies. We will apply our proven, partnership-led model to develop tailored programmes that benefit people with haemophilia and haemoglobinopathies, their healthcare professionals, and families – always adapted to local needs.
Let us tell you more here.”
Keep up with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis